Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GARP monoclonal antibody DS-1055a

An afucosylated human monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, anti-GARP monoclonal antibody DS-1055a selectively targets and binds to GARP and depletes GARP-positive regulatory T cells (Tregs). This leads to a reversal of immunosuppression mediated by GARP-positive Tregs and enhances the immune response to tumor cells. GARP, a transmembrane protein highly expressed on activated, immunosuppressive Tregs in the tumor microenvironment (TME), is essential for the expression of TGFbeta on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function and the immunosuppressive nature of Tregs.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-glycoprotein A repetitions predominant monoclonal antibody DS-1055a
Code name:DS 1055a
DS-1055a
DS1055a
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search